Last reviewed · How we verify

Manexin (mannite hexanitrate)

unknown active ✓ Verified May 2026

Manexin (generic name: mannite hexanitrate) is a drug. It is currently in unknown development.

Manexin works by binding to specific biological molecules to produce a therapeutic effect.

Manexin is a small molecule with the synonyms D-MANNITOL HEXANITRATE, HEXANITRATE DE MANNITOL, and others. Its modality is classified as a small molecule.

At a glance

Generic namemannite hexanitrate
Therapeutic areaOther
Phaseunknown

Mechanism of action

Imagine Manexin as a key that fits into a specific lock in the body. When it binds to that lock, it can turn on or off certain processes that help to treat a particular disease or condition. This is a simplified way of understanding how small molecules like Manexin work to produce their effects.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Manexin

What is Manexin?

Manexin (mannite hexanitrate) is a pharmaceutical drug.

How does Manexin work?

Manexin works by binding to specific biological molecules to produce a therapeutic effect.

What is the generic name of Manexin?

mannite hexanitrate is the generic (nonproprietary) name of Manexin.

What development phase is Manexin in?

Manexin is in unknown.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing